Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP: BAYRY )

15.02 +0.15 (+1.01%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 564,555
Open 14.79
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 14.87
Today's Range 14.70 - 15.02
52wk Range 12.45 - 18.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.) 
Via Benzinga
BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products
 
Via Benzinga

Performance

YTD
+11.59%
+11.59%
1 Month
-15.38%
-15.38%
3 Month
-16.28%
-16.28%
6 Month
+11.59%
+11.59%
1 Year
-2.34%
-2.34%

More News

Read More
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Via Benzinga
7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend
Via InvestorPlace
Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off
Via Benzinga
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
Via Benzinga
Recap: Bayer Q4 Earnings
Via Benzinga
Three Stocks To Buy In This Bear Market
Via Talk Markets
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows
Via Benzinga
Investment Strategy Monthly Insights, April 2022
Via Talk Markets
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
Via Benzinga
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up?
Via Investor's Business Daily
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn
Via InvestorPlace
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Via Investor's Business Daily
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
Via Benzinga
Why Are Evotec Shares Trading Lower On Friday?
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Via Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.